Lyell Immunopharma, Inc. (LYEL) Shareholders’ equity 2019–2025
Lyell Immunopharma, Inc. (LYEL) shareholders’ equity at each fiscal year-end, per SEC filings.
$248.2MFY2025 · since FY2019: -$111.1M → $248.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $248.2M | -35.2% |
| FY2024 | $382.8M | -41.5% |
| FY2023 | $655.0M | -21.4% |
| FY2022 | $833.3M | -10.4% |
| FY2021 | $929.8M | +417.8% |
| FY2020 | -$292.5M | -163.3% |
| FY2019 | -$111.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice